CELL INTELLIGENCE · 肿瘤细胞治疗研究

elranatamab 与医生选择治疗方案（非 BCMA 靶向方案）用于日本三类暴露多发性骨髓瘤患者的成本效果分析

Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed m

从医疗支付方角度来看，在基础案例和情景分析中，elranatamab 相较于 PCT 具有成本效益，其 ICER 始终低于日本通常接受的阈值；但鉴于非锚定 MAIC 和长期外推的不确定性，应谨慎解读这一结果。

CAR-T 细胞疗法治疗多发性骨髓瘤的疗效决定因素与优化：现状与未来展望

Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspec

抗 B 细胞成熟抗原 CAR-T 治疗后原有结节病发作：模拟髓外骨髓瘤复发的皮肤病变

Flare of Pre-Existing Sarcoidosis After Anti-B-Cell Maturation Antigen CAR-T Therapy: Cutaneous Lesions Mimicking Extramedullary Myeloma Relapse.

迟发性帕金森综合征可能相关于 elranatamab 治疗复发/难治性多发性骨髓瘤：一例特征不明确的神经系统事件病例报告

Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characte

AML/MDS 细胞治疗的最新进展

Recent advances in cell therapy for AML/MDS.

弥漫大 B 细胞淋巴瘤 axicabtagene ciloleucel 治疗后持续性帕金森综合征伴多巴胺能去神经支配：一例病例报告

Persistent parkinsonism with dopaminergic denervation following axicabtagene ciloleucel therapy for diffuse large B cell lymphoma: a case report.

含环磷酰胺强化多药桥接治疗对多发性骨髓瘤 idecabtagene vicleucel 治疗后结局的影响

Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.

CAR-T 细胞疗法的癌症特异性细胞表面靶点鉴定

Identification of cancer-specific cell surface targets for CAR-T cell therapy.

病例报告：自体干细胞输注使 BCMA 靶向双特异性抗体治疗所致多发性骨髓瘤严重血细胞减少后造血功能得以恢复

Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in

NOG 小鼠中 BCMA-CAR 治疗多发性骨髓瘤可阻止贫血与骨病变进展

BCMA-CAR Therapy for Multiple Myeloma in NOG Mice Prevents the Progression of Anemia and Bone Lesions.